- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00902291
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
A disease assessment will be performed at study week 8 (± 3 days) by the investigator. The assessment will be based both on changes in clinical symptoms, and radiographic images. Subjects without evidence of disease progression may continue to receive treatment based on their original treatment assignment until disease progression or intolerability. Disease assessments will be performed every 8 weeks during the extended period. A safety follow-up visit will occur 4 weeks after the last dose infusion of AGS-1C4D4 and/or gemcitabine.
Post-Treatment: Subjects terminating from protocol therapy for reasons unrelated to documented disease progression will be followed by telephone contact every 2 months until they begin a new anticancer therapy, their disease progresses, they die, become lost to follow-up or withdrawal consent for further follow-up, whichever of these events occurs first.
Overall survival: All subjects will be followed by telephone contact every 2 months until death, loss to follow-up, or withdrawal of consent, whichever of these events occurs first.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Cross Cancer Institute
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Juravinski Cancer Centre
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
-
-
-
Clermont-Ferrand, Frankrijk
- CHU Estaing
-
Le Mans Cedex, Frankrijk
- Centre Jean Bernard, Oncologie médicale
-
Lille, Frankrijk
- Centre Régional de Lutte Contre le Cancer-Centre Oscar Lambret
-
Pessac, Frankrijk
- Hôpital du Haut Lèvêque, Service d'Hepato Gastroentérologie
-
Poitiers Cedex, Frankrijk
- Centre Hospitalier Universitaire de Poitiers
-
Rouen, Frankrijk
- Hôpital Charles Nicolle
-
-
-
-
-
Arkhangelsk, Russische Federatie
- State Institution of Healthcare "Arkhangelsk Regional Clinical Oncology Dispensary"
-
Ivanovo, Russische Federatie
- Regional Oncology Dispensary
-
Kazan, Russische Federatie
- Clinical Oncology Dispensary of Republic of Tatarstan
-
Kuzmolovo, Russische Federatie
- State Healthcare Institution "Leningrad Regional Oncologic Dispensary"
-
Moscow, Russische Federatie
- Non-state Healthcare Institution N.A. Semashko Central Clinical Hospital #2 of JSC "Russian Railway"
-
Obninsk, Russische Federatie
- Medical Radiology Research Center of Russian Medical Academy
-
Omsk, Russische Federatie
- State Healthcare Institution of Omsk Region "Clinical Oncologic Dispensary"
-
Saint Petersburg, Russische Federatie
- State Educational Institution "S.M. Kirov Military Medical Academy of Ministry of Defense of Russia"
-
St. Petersburg, Russische Federatie
- Saint Petersburg State Healthcare Institution "Municipal Clinical Oncology Dispensary"
-
-
-
-
-
Barcelona, Spanje
- Hospital Clinic i Provincial de Barcelona, Servicio de Oncologia
-
Madrid, Spanje
-
Toledo, Spanje
- Hospital Virgen de la Salud, Servicio Oncologia
-
-
-
-
California
-
La Jolla, California, Verenigde Staten, 92093
- University of California San Diego Medical Center
-
-
Florida
-
Boynton Beach, Florida, Verenigde Staten, 33435
- Palm Beach Institute of Hematology and Oncology
-
Miami, Florida, Verenigde Staten, 33136
- University of Miami
-
-
Louisiana
-
Baton Rouge, Louisiana, Verenigde Staten, 70809
- Medical Oncology LLC
-
-
Maryland
-
Annapolis, Maryland, Verenigde Staten, 21401
- Annapolis Oncology Center
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02115
- Dana Farber Cancer Center
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55407
- Virginia G. Piper Cancer Center
-
-
New York
-
New York, New York, Verenigde Staten, 10021
- Memorial Sloan Kettering Cancer Center
-
Syracuse, New York, Verenigde Staten, 13210
- Regional Oncology Center
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97227
- Kaiser Permanente Northwest Region Oncology Hematology
-
-
South Carolina
-
Greenville, South Carolina, Verenigde Staten, 29605
- Cancer Centers of the Carolinas
-
-
Tennessee
-
Knoxville, Tennessee, Verenigde Staten, 37920
- Baptist Regional Cancer Center
-
Nashville, Tennessee, Verenigde Staten, 37232
- Vanderbilt University Medical Center, Div. of Medical Oncology
-
-
Virginia
-
Lynchburg, Virginia, Verenigde Staten, 24501
- Alan B. Pearson Regional Cancer Center Lynchburg Hematology Oncology Clinic
-
-
Wisconsin
-
Milwaukee, Wisconsin, Verenigde Staten, 53226
- Medical College of Wisconsin
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Pathologically confirmed metastatic adenocarcinoma of the pancreas (AJCC Stage IV). Subjects with islet cell neoplasms are excluded
- Non-measurable or measurable disease based on the RECIST criteria
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Life expectancy of > 3 months
Hematologic function, as follows:
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Platelet count ≥ 100 x 109/L
- Hemoglobin ≥ 9 g/dL (transfusion independent)
Renal function, as follows:
- Creatinine ≤ 2.0 mg/dL
Hepatic function, as follows:
- Aspartate aminotransferase (AST) ≤ 2.5 x ULN or ≤ 5 x ULN if known liver metastases.
- Alanine aminotransferase (ALT) ≤ 2.5 x ULN or ≤ 5 x ULN if known liver metastases
- Bilirubin ≤ 2 x ULN
- INR < 1.3 (or ≤ 3 if on warfarin for therapeutic anti-coagulation)
Exclusion Criteria:
Prior systemic therapy for metastatic pancreatic cancer
- Subjects who have received adjuvant treatment with gemcitabine and who had relapse metastatically are allowed
- Subjects with advanced local disease who have received treatment with gemcitabine and in whom progression has been observed with the onset of metastases less than 6 months are excluded
- Chemotherapy and/or radiation within 4 weeks of study enrollment
- Prior monoclonal antibody therapy within 60 days of study enrollment
- Known brain or leptomeningeal disease
History of other primary malignancy, unless:
- Curatively resected non-melanomatous skin cancer
- Other malignancy curatively treated with no known active disease present and no treatment administered for the last 3 years
- Active angina or Class III or IV Congestive Heart Failure (New York Heart Association CHF Functional Classification System)
- Use of any investigational product within 4 weeks of study enrollment
- Major surgery (that requires general anesthesia) within 4 weeks before study enrollment
- Women who are pregnant (confirmed by positive pregnancy test) or lactating
- Man or woman of childbearing potential not consenting to use adequate contraceptive precautions during the course of the study and for 4 weeks after the last AGS-1C4D4 and/or gemcitabine infusion administration
- Subject known to be human immunodeficiency, hepatitis B or hepatitis C virus positive
- Active serious infection not controlled with antibiotics
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Actieve vergelijker: 1. Gemcitabine monotherapy
|
IV infusion
|
Experimenteel: 2. Gemcitabine plus AGS-1C4D4
|
IV infusion
IV infusion
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Survival rate at 6 months
Tijdsspanne: 6 months
|
6 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Overall Survival (OS)
Tijdsspanne: Throughout treatment period and post-treatment every 2 months until death, or subject discontinues the study
|
Throughout treatment period and post-treatment every 2 months until death, or subject discontinues the study
|
Progression free survival (PFS)
Tijdsspanne: Throughout treatment period or post-treatment every 2 months until disease progression or death, respectively, or subject discontinues the study
|
Throughout treatment period or post-treatment every 2 months until disease progression or death, respectively, or subject discontinues the study
|
Change in level of serum tumor marker CA 19-9
Tijdsspanne: Week 1, Week 4, Week 7 and every 3 weeks during the extended treatment period
|
Week 1, Week 4, Week 7 and every 3 weeks during the extended treatment period
|
Incidence of anti-AGS-1C4D4 antibody formation
Tijdsspanne: Week 1, Week 7 and every 8 weeks during the extended treatment period
|
Week 1, Week 7 and every 8 weeks during the extended treatment period
|
Objective Response Rate (Partial Response or better per RECIST criteria version 1.1
Tijdsspanne: Week 8, and every 8 weeks during the extended treatment period
|
Week 8, and every 8 weeks during the extended treatment period
|
Disease Control (Stable Disease or better per RECIST criteria)
Tijdsspanne: Week 8, and every 8 weeks during the extended treatment period
|
Week 8, and every 8 weeks during the extended treatment period
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie directeur: Chief Medical Officer, Agensys, Inc.
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het spijsverteringsstelsel
- Neoplasmata per histologisch type
- Neoplasmata
- Neoplasmata per site
- Adenocarcinoom
- Carcinoom
- Neoplasmata, glandulair en epitheel
- Endocriene systeemziekten
- Neoplasmata van het spijsverteringsstelsel
- Endocriene klierneoplasmata
- Neoplasmata, ductaal, lobulair en medullair
- Carcinoom, ductaal
- Pancreasneoplasmata
- Alvleesklier Ziekten
- Carcinoom, ductaal pancreas
- Fysiologische effecten van medicijnen
- Moleculaire mechanismen van farmacologische werking
- Anti-infectieuze middelen
- Antivirale middelen
- Enzymremmers
- Antimetabolieten, antineoplastische
- Antimetabolieten
- Antineoplastische middelen
- Immunosuppressieve middelen
- Immunologische factoren
- Gemcitabine
Andere studie-ID-nummers
- 2008002
- 2009-009194-99 (EudraCT-nummer)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Alvleesklierkanker
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
Andrei IagaruNiet meer beschikbaarCarcinoïde tumoren | Eilandcel (Pancreatic NET) | Andere neuro-endocriene tumorenVerenigde Staten
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
University of Southern CaliforniaNational Cancer Institute (NCI)WervingLokaal gevorderd pancreasadenocarcinoom | Inoperabel pancreasadenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Nog niet aan het wervenAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
Klinische onderzoeken op Gemcitabine
-
Dokuz Eylul UniversityNog niet aan het wervenBlaaskanker | Gemcitabine | BCG | Docetaxel | Intravesicale instillatieKalkoen
-
Insel Gruppe AG, University Hospital BernSwiss Cancer LeagueNog niet aan het werven
-
German Society for Pediatric Oncology and Hematology...Deutsche Krebshilfe e.V., Bonn (Germany)WervingNasofarynxcarcinoom | Nasofaryngeale kanker | Nasofarynxkanker | Nasofaryngeale neoplasmataDuitsland